Back to top
more

STEALTH BIOTHER (MITO)

(Delayed Data from NSDQ)

$14.62 USD

14.62
868

-0.26 (-1.75%)

Updated May 3, 2019 11:05 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[MITO]

Reports for Purchase

Showing records 1 - 20 ( 36 total )

Industry: Medical - Biomedical and Genetics

Record: 1

07/14/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

06/16/2022

Company Report

Pages: 5

New Clinical Data Could Support NDA Submission for Barth Syndrome; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

06/09/2022

Company Report

Pages: 7

Preclinical SBT-272 Data in Neuromuscular Disease Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

06/01/2022

Company Report

Pages: 6

Orphan Drug Designation Granted in Europe; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

05/23/2022

Company Report

Pages: 6

1Q22 Financial Results Reported; Reiterate Buy; Lowering PT to $1.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

04/11/2022

Company Report

Pages: 6

2021 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

03/17/2022

Company Report

Pages: 6

Preclinical Duchenne Muscular Dystrophy Data Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

02/16/2022

Company Report

Pages: 6

Phase 2 Dry AMD Trial Completes Patient Treatment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

01/12/2022

Company Report

Pages: 6

Positive Update on Duchenne Muscular Dystrophy Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MITO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

06/02/2021

Company Report

Pages: 6

Elamipretide Orphan Drug Designation Granted in Europe; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

05/20/2021

Company Report

Pages: 6

A Pathway to Potential Approval in Barth Syndrome; 1Q21 Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

08/28/2020

Daily Note

Pages: 5

We are updating coverage of our Healthcare sector to better allocate our research resources in

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

06/12/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

06/12/2020

Company Report

Pages: 8

Dial in Today at 12PM to Our Cardiolipin Expert Call

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

06/11/2020

Company Report

Pages: 8

Dial in Tomorrow at 12PM to Our Cardiolipin Expert Call

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

06/05/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

06/05/2020

Company Report

Pages: 8

Dial in on June 12 to Our Cardiolipin Expert Call

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

06/03/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 20

06/02/2020

Company Report

Pages: 8

Dial in on June 12 to Learn Why Cardiolipin Holds the Key in Cardiomyopathy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party
// eof